Needham Reiterates Hold on Revance Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Hold rating on Revance Therapeutics (NASDAQ:RVNC).

October 28, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Serge Belanger has reiterated a Hold rating on Revance Therapeutics, indicating a neutral stance on the stock.
The reiteration of a Hold rating by Needham suggests that the analyst does not see significant short-term upside or downside potential for Revance Therapeutics. This neutral stance is likely to result in minimal immediate impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100